UMG1/CD3ε双特异性T细胞衔接器重定向T细胞对弥漫大B细胞淋巴瘤的细胞毒性
研究分析弥漫大B细胞淋巴瘤(DLBCL)中UMG1表达,并构建新型不对称UMG1/CD3ε双特异性T细胞衔接器(BTCE)。免疫组化显示20%-24% DLBCL高表达UMG1,包括BCL2高表达和CD20低表达侵袭性病例;该BTCE可诱导重定向细胞毒性,并与来那度胺协同。
要点
- UMG1在20%-24%的DLBCL中高表达,包括BCL2高表达和CD20低表达病例。
- UMG1在DLBCL骨髓浸润细胞和建系细胞中也有膜表达。
- UMG1/CD3ε-BTCE诱导针对DLBCL细胞的重定向细胞毒性,与来那度胺协同。
核心结论
- UMG1/CD3ε-BTCE是DLBCL有前景的治疗手段。
研究设计与样本
- 研究采用组织微阵列和病理切片免疫组化分析DLBCL中UMG1表达,并构建新型不对称UMG1/CD3ε-BTCE进行功能评价。
主要发现
- 免疫组化显示20%-24%的DLBCL高表达UMG1,包括高度侵袭性BCL2高表达和CD20低表达病例。
- UMG1膜表达也见于DLBCL骨髓浸润细胞和建系细胞。
- UMG1/CD3ε-BTCE诱导针对DLBCL细胞的重定向细胞毒性,并与来那度胺协同。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UMG1 is a unique epitope of CD43, not expressed by normal cells and tissues of haematopoietic and non-haematopoietic origin, except thymocytes and a minority (<5%) of peripheral blood T lymphocytes. By immunohistochemistry analysis of tissue microarray and pathology slides, we found high UMG1 expression in 20%-24% of diffuse large B-cell lymphomas (DLBCLs), including highly aggressive BCL2high and CD20low cases. UMG1 membrane expression was also found in DLBCL bone marrow-infiltrating cells and established cell lines. Targeting UMG1 with a novel asymmetric UMG1/CD3ε-bispecific T-cell engager (BTCE) induced redirected cytotoxicity against DLBCL cells and was synergistic with lenalidomide. We conclude that UMG1/CD3ε-BTCE is a promising therapeutic for DLBCLs.
引用
- Caracciolo D, Polerà N, Belmonte B, et al. UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma. Br J Haematol. 2023. PMID: 37963444. doi:10.1111/bjh.19183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。